Damora Therapeutics (DMRA) Exchange Rate Effect (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Exchange Rate Effect came in at -$48000.0 in Q1 2026, down 123.65% YoY from $203000.0 in Q1 2025, and down 166.67% on a QoQ basis from -$18000.0 in Q4 2025.
Damora Therapeutics (DMRA) Exchange Rate Effect (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Exchange Rate Effect data on file, last reported at -$48000.0 in Q1 2026.
- Quarterly Exchange Rate Effect fell 123.65% year-over-year to -$48000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $454000.0 (up 1846.15% YoY) and the FY2025 annual result came in at $705000.0, up 322.4% from the prior year.
- Exchange Rate Effect retreated to -$48000.0 in Q1 2026, from -$18000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $1.5 million in Q4 2022 to a low of -$720000.0 in Q2 2022.
- A 5-year average of $58117.6 and a median of -$18000.0 in 2025 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2022 — Exchange Rate Effect jumped 949.15% — and 2024, when it sank 563.16%.
- Tracing DMRA's Exchange Rate Effect over 5 years: stood at $1.5 million in 2022, then plunged by 81.3% to $281000.0 in 2023, then plunged by 301.78% to -$567000.0 in 2024, then jumped by 96.83% to -$18000.0 in 2025, then plunged by 166.67% to -$48000.0 in 2026.
- The last three Exchange Rate Effect figures came in at -$48000.0 (Q1 2026), -$18000.0 (Q4 2025), and $11000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | -22,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22,000.00 |
| Jun 30, 2026 | -22,000.00 |
| Mar 31, 2026 | -48,000.00 |
| Mar 31, 2026 | -48,000.00 |
| Dec 31, 2025 | -18,000.00 |
| Dec 31, 2025 | -18,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 509,000.00 |
| Jun 30, 2025 | 509,000.00 |
| Mar 31, 2025 | 203,000.00 |
| Mar 31, 2025 | 203,000.00 |
| Dec 31, 2024 | -567,000.00 |
| Dec 31, 2024 | -567,000.00 |
| Sep 30, 2024 | 467,000.00 |
| Sep 30, 2024 | 467,000.00 |
| Jun 30, 2024 | -129,000.00 |
| Jun 30, 2024 | -129,000.00 |
| Mar 31, 2024 | -88,000.00 |
| Mar 31, 2024 | -88,000.00 |